The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease

Patients with sickle cell disease (SCD) who undergo repeated blood transfusions often develop iron overload. Deferiprone (Ferriprox®) is an oral iron chelator indicated for the treatment of transfusional iron overload due to thalassemia syndromes and has been recently approved as a treatment for iro...

Descripción completa

Detalles Bibliográficos
Autores principales: Soulières, Denis, Mercier-Ross, Jules, Fradette, Caroline, Rozova, Anna, Tsang, Yu Chung, Tricta, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810455/
https://www.ncbi.nlm.nih.gov/pubmed/34981144
http://dx.doi.org/10.1007/s00277-021-04728-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810455/
https://www.ncbi.nlm.nih.gov/pubmed/34981144
http://dx.doi.org/10.1007/s00277-021-04728-0

Ejemplares similares